Elsa Rodrigues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elsa Rodrigues has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Maria João Gama
Research Institute for Medicines (iMed.ULisboa), Portugal
23 shared publications - Maria João Nunes
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal
19 shared publications - Margarida Castro-Caldas
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
16 shared publications - Andreia Neves Carvalho
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
10 shared publications - CecIlia Maria Pereira Rodrigues
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
10 shared publications - Inês Milagre
Universidade Católica Portuguesa
8 shared publications
Latest Publications
- Open Access
- 22 December 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (3) , 166993
Cholesterol redistribution triggered by CYP46A1 gene therapy improves major hallmarks of Niemann-Pick type C disease but is not sufficient to halt neurodegeneration
- 22 December 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (3) , 166993
Open AccessCholesterol redistribution triggered by CYP46A1 gene therapy improves major hallmarks of Niemann-Pick type C disease but is not sufficient to halt neurodegeneration
- Open Access
- 5 December 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (2) , 166980
NPC1-like phenotype, with intracellular cholesterol accumulation and altered mTORC1 signaling in models of Parkinson's disease
- 5 December 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (2) , 166980
Open AccessNPC1-like phenotype, with intracellular cholesterol accumulation and altered mTORC1 signaling in models of Parkinson's disease
- Open Access
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 35
Cysteine redox post-translational modifications: the missing link between redox-signalling and mitochondrial dynamics and function in Parkinson’s disease?
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 35
Open AccessCysteine redox post-translational modifications: the missing link between redox-signalling and mitochondrial dynamics and function in Parkinson’s disease?
- 1 April 2019
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 96, 1-9
Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy
- 1 April 2019
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 96, 1-9
Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy
- Open Access
- 1 January 2019
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 13
Targeting cholesterol metabolism in neuroblastoma by acting on HDACs
A wide range of brain disorders are associated with imbalances in protein acetylation levels and treatment with various histone deacetylase (HDAC) inhibitors (HDACi) has been shown to correct these deficiencies, emerging as a promising new strategy for therapeutic intervention in neurodegenerative diseases. We have demonstrated that in neuroblastoma cells HDACi dramatically increase mRNA levels of genes involved in cholesterol efflux and elimination, while decreasing the expression of genes involved in synthesis and uptake, leading to a decrease in intracellular cholesterol content. These results suggested that this class of compounds could potentially be used to modulate brain cholesterol metabolism in pathological conditions. We used primary cultures of mice neurons and astrocytes treated with the pan-HDACi trichostatin A, and with class-specific HDAC inhibitors, namely, the class I inhibitor Mocetinostat (MGCD0103) and the class II (IIa) inhibitor MC1568, to evaluate the mRNA levels of a panel of genes involved in cholesterol synthesis, up-take, transport and elimination. Although we could only partially recapitulate the results obtained in the neuroblastoma cells, we could identify class I HDACs as major modulators of neuronal cholesterol homeostasis. In addition, when comparing the expression profiles of neurons and astrocytes, we identified Mvk, Cyp46a1 and Apoe as genes that are affected by both TSA and MGCD0103 in both cells. In order to further dissect the role of class I HDACs we specifically silenced class I HDACs by transfecting TALEN specific plasmids in SH-SY5Y neuroblastoma cells. Our results point to a role of class I HDACs as therapeutic targets both in neuroblastoma and neurodegenerative disorders with disturbances in cholesterol homeostasis.
- 1 January 2019
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 13
Open AccessTargeting cholesterol metabolism in neuroblastoma by acting on HDACs
A wide range of brain disorders are associated with imbalances in protein acetylation levels and treatment with various histone deacetylase (HDAC) inhibitors (HDACi) has been shown to correct these deficiencies, emerging as a promising new strategy for therapeutic intervention in neurodegenerative diseases. We have demonstrated that in neuroblastoma cells HDACi dramatically increase mRNA levels of genes involved in cholesterol efflux and elimination, while decreasing the expression of genes involved in synthesis and uptake, leading to a decrease in intracellular cholesterol content. These results suggested that this class of compounds could potentially be used to modulate brain cholesterol metabolism in pathological conditions. We used primary cultures of mice neurons and astrocytes treated with the pan-HDACi trichostatin A, and with class-specific HDAC inhibitors, namely, the class I inhibitor Mocetinostat (MGCD0103) and the class II (IIa) inhibitor MC1568, to evaluate the mRNA levels of a panel of genes involved in cholesterol synthesis, up-take, transport and elimination. Although we could only partially recapitulate the results obtained in the neuroblastoma cells, we could identify class I HDACs as major modulators of neuronal cholesterol homeostasis. In addition, when comparing the expression profiles of neurons and astrocytes, we identified Mvk, Cyp46a1 and Apoe as genes that are affected by both TSA and MGCD0103 in both cells. In order to further dissect the role of class I HDACs we specifically silenced class I HDACs by transfecting TALEN specific plasmids in SH-SY5Y neuroblastoma cells. Our results point to a role of class I HDACs as therapeutic targets both in neuroblastoma and neurodegenerative disorders with disturbances in cholesterol homeostasis.
- Open Access
- 1 January 2019
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 13
CYP46A1 expression modulates mitochondrial function and integrity in Niemann-Pick type C disease
Dysfunctions in brain cholesterol homeostasis have been extensively related to brain disorders. The neuronal-specific CYP46A1 is responsible for the conversion of cholesterol into 24S-hydroxycholesterol, the major pathway for brain cholesterol elimination. Interestingly, increased expression of this hydroxylase improves cognition, while its reduction leads to a poor cognitive performance. Moreover, increasing amount of epidemiological, biochemical and molecular evidence suggests that CYP46A1 has a role in the pathogenesis or progression of neurodegenerative disorders, in which the up-regulation of this enzyme is clearly beneficial. We have identified that membrane cholesterol reduction by CYP46A1 is the necessary trigger to increased neuronal dendritic outgrowth and dendritic protrusion density, and to elicit in vitro and in vivo increase of synaptic proteins in crude synaptosomal fractions. Taking into account its role in cholesterol reduction and neuronal function, we hypothesized that CYP46A1 could be a potential therapeutic target in Niemann Pick Type C Disease (NPC). Human fibroblasts from NPC1 and NPC2 patients and stable NPC1-knockdown human neuroblastoma cells, were transduced with and an adenovirus encoding green fluorescent protein (GFP), or GFP and CYP46A1 and maintained for 96h. In NPC fibroblasts ectopic expression of CYP46A1 led to a reduction in cholesterol accumulation and sequestration in the late endosome/ lysosome compartment. Moreover, CYP46A1 expression partially restored the mRNA levels of cholesterol homeostasis related genes. In stable NPC1-knockdown SH-SY5Y cells, CYP46A1 ectopic expression, could also reduce cholesterol accumulation, and concomitantly rescue mitochondrial function and integrity, modulating mitochondria dynamics in favor of mitochondrial fusion. These data suggests that regulation of neuronal CYP46A1 might be a novel and promising strategy for NPC disease.
- 1 January 2019
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 13
Open AccessCYP46A1 expression modulates mitochondrial function and integrity in Niemann-Pick type C disease
Dysfunctions in brain cholesterol homeostasis have been extensively related to brain disorders. The neuronal-specific CYP46A1 is responsible for the conversion of cholesterol into 24S-hydroxycholesterol, the major pathway for brain cholesterol elimination. Interestingly, increased expression of this hydroxylase improves cognition, while its reduction leads to a poor cognitive performance. Moreover, increasing amount of epidemiological, biochemical and molecular evidence suggests that CYP46A1 has a role in the pathogenesis or progression of neurodegenerative disorders, in which the up-regulation of this enzyme is clearly beneficial. We have identified that membrane cholesterol reduction by CYP46A1 is the necessary trigger to increased neuronal dendritic outgrowth and dendritic protrusion density, and to elicit in vitro and in vivo increase of synaptic proteins in crude synaptosomal fractions. Taking into account its role in cholesterol reduction and neuronal function, we hypothesized that CYP46A1 could be a potential therapeutic target in Niemann Pick Type C Disease (NPC). Human fibroblasts from NPC1 and NPC2 patients and stable NPC1-knockdown human neuroblastoma cells, were transduced with and an adenovirus encoding green fluorescent protein (GFP), or GFP and CYP46A1 and maintained for 96h. In NPC fibroblasts ectopic expression of CYP46A1 led to a reduction in cholesterol accumulation and sequestration in the late endosome/ lysosome compartment. Moreover, CYP46A1 expression partially restored the mRNA levels of cholesterol homeostasis related genes. In stable NPC1-knockdown SH-SY5Y cells, CYP46A1 ectopic expression, could also reduce cholesterol accumulation, and concomitantly rescue mitochondrial function and integrity, modulating mitochondria dynamics in favor of mitochondrial fusion. These data suggests that regulation of neuronal CYP46A1 might be a novel and promising strategy for NPC disease.
- 12 April 2018
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (12) , 9139-9155
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson’s Disease
Parkinson’s disease (PD) is characterized by severe motor symptoms, and currently there is no treatment that retards disease progression or reverses damage prior to the time of clinical diagnosis. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD; however, its effect in PD motor symptoms has never been addressed. In the present work, an extensive behavior analysis was performed to better characterize the MPTP model of PD and to evaluate the effects of TUDCA in the prevention/improvement of mice phenotype. MPTP induced significant alterations in general motor performance paradigms, including increased latency in the motor swimming, adhesive removal and pole tests, as well as altered gait, foot dragging, and tremors. TUDCA administration, either before or after MPTP, significantly reduced the swimming latency, improved gait quality, and decreased foot dragging. Importantly, TUDCA was also effective in the prevention of typical parkinsonian symptoms such as spontaneous activity, ability to initiate movement and tremors. Accordingly, TUDCA prevented MPTP-induced decrease of dopaminergic fibers and ATP levels, mitochondrial dysfunction and neuroinflammation. Overall, MPTP-injected mice presented motor symptoms that are aggravated throughout time, resembling human parkinsonism, whereas PD motor symptoms were absent or mild in TUDCA-treated animals, and no aggravation was observed in any parameter. The thorough demonstration of improvement of PD symptoms together with the demonstration of the pathways triggered by TUDCA supports a subsequent clinical trial in humans and future validation of the application of this bile acid in PD.
- 12 April 2018
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (12) , 9139-9155
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson’s Disease
Parkinson’s disease (PD) is characterized by severe motor symptoms, and currently there is no treatment that retards disease progression or reverses damage prior to the time of clinical diagnosis. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD; however, its effect in PD motor symptoms has never been addressed. In the present work, an extensive behavior analysis was performed to better characterize the MPTP model of PD and to evaluate the effects of TUDCA in the prevention/improvement of mice phenotype. MPTP induced significant alterations in general motor performance paradigms, including increased latency in the motor swimming, adhesive removal and pole tests, as well as altered gait, foot dragging, and tremors. TUDCA administration, either before or after MPTP, significantly reduced the swimming latency, improved gait quality, and decreased foot dragging. Importantly, TUDCA was also effective in the prevention of typical parkinsonian symptoms such as spontaneous activity, ability to initiate movement and tremors. Accordingly, TUDCA prevented MPTP-induced decrease of dopaminergic fibers and ATP levels, mitochondrial dysfunction and neuroinflammation. Overall, MPTP-injected mice presented motor symptoms that are aggravated throughout time, resembling human parkinsonism, whereas PD motor symptoms were absent or mild in TUDCA-treated animals, and no aggravation was observed in any parameter. The thorough demonstration of improvement of PD symptoms together with the demonstration of the pathways triggered by TUDCA supports a subsequent clinical trial in humans and future validation of the application of this bile acid in PD.
- Open Access
- 27 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-16
Evidences for a New Role of miR-214 in Chondrogenesis
MiR-214 is known to play a role in mammalian skeletal development through inhibition of osteogenesis and stimulation of osteoclastogenesis, but data regarding other vertebrates, as well as a possible role in chondrogenesis, remain unknown. Here, we show that miR-214 expression is detected in bone and cartilage of zebrafish skeleton, and is downregulated during murine ATDC5 chondrocyte differentiation. Additionally, we observed a conservation of the transcriptional regulation of miR-214 primary transcript Dnm3os in vertebrates, being regulated by Ets1 in ATDC5 chondrogenic cells. Moreover, overexpression of miR-214 in vitro and in vivo mitigated chondrocyte differentiation probably by targeting activating transcription factor 4 (Atf4). Indeed, miR-214 overexpression in vivo hampered cranial cartilage formation of zebrafish and coincided with downregulation of atf4 and of the key chondrogenic players sox9 and col2a1. We show that miR-214 overexpression exerts a negative role in chondrogenesis by impacting on chondrocyte differentiation possibly through conserved mechanisms.
- 27 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-16
Open AccessEvidences for a New Role of miR-214 in Chondrogenesis
MiR-214 is known to play a role in mammalian skeletal development through inhibition of osteogenesis and stimulation of osteoclastogenesis, but data regarding other vertebrates, as well as a possible role in chondrogenesis, remain unknown. Here, we show that miR-214 expression is detected in bone and cartilage of zebrafish skeleton, and is downregulated during murine ATDC5 chondrocyte differentiation. Additionally, we observed a conservation of the transcriptional regulation of miR-214 primary transcript Dnm3os in vertebrates, being regulated by Ets1 in ATDC5 chondrogenic cells. Moreover, overexpression of miR-214 in vitro and in vivo mitigated chondrocyte differentiation probably by targeting activating transcription factor 4 (Atf4). Indeed, miR-214 overexpression in vivo hampered cranial cartilage formation of zebrafish and coincided with downregulation of atf4 and of the key chondrogenic players sox9 and col2a1. We show that miR-214 overexpression exerts a negative role in chondrogenesis by impacting on chondrocyte differentiation possibly through conserved mechanisms.
- 1 November 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 360 (1) , 55-60
The mevalonate pathway in neurons: It's not just about cholesterol
- 1 November 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 360 (1) , 55-60
The mevalonate pathway in neurons: It's not just about cholesterol
- 1 September 2017
- Published by Elsevier in Experimental Neurology
- Vol. 295, 77-87
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease
- 1 September 2017
- Published by Elsevier in Experimental Neurology
- Vol. 295, 77-87
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease